Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Varun Varadarajan

Otology & Neurotology Sacramento, CA Medical Doctor

NPI 1508285693 CMS profile 2789267

1111 Exposition Blvd Bldg 700, Sacramento, CA 95815

Open in the dashboard

General payments

$26,850

73 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Varun Varadarajan of Sacramento, CA is reported in the CMS Open Payments database as having received $26,850 across 73 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Otology & Neurotology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,994 18
2024 General $11,900 30
2023 General $2,345 11
2022 General $411 8
2021 General $87 5
2020 General $113 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Varun Varadarajan
  • Otology & Neurotology median
  • Middle half of Otology & Neurotology
  • National median

In program year 2025, general payments to Varun Varadarajan were reported at $11,994. Among 280 Otology & Neurotology profiles paid that year, the median was $411 and the middle half received between $148 and $1,608.

Show as a table
Year Varun Varadarajan Otology & Neurotology median Middle half National median
2019 $0 $349 $117–$1,358 $163
2020 $113 $118 $58–$325 $114
2021 $87 $186 $81–$600 $132
2022 $411 $290 $129–$938 $149
2023 $2,345 $335 $119–$978 $160
2024 $11,900 $399 $138–$1,384 $164
2025 $11,994 $411 $148–$1,608 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Cochlear Americas $24,703 42 payments
  2. Stryker Corporation $1,408 13 payments
  3. Aerin Medical Inc. $183 1 payment
  4. Inspire Medical Systems, Inc. $125 1 payment
  5. Advanced Bionics, LLC $119 5 payments
  6. AstraZeneca Pharmaceuticals LP $113 1 payment
  7. MED-EL Corporation $94 5 payments
  8. KLS-Martin L.P. $34 1 payment
  9. iotaMotion, Inc $25 1 payment
  10. kaleo, Inc. $19 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $22,200 6 payments
  2. Food and Beverage $2,539 56 payments
  3. Travel and Lodging $2,111 11 payments
Products named General payments · program years 2020–2025
  1. BAHA $24,703 42 payments
  2. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $24,519 39 payments
  3. OSIA OSI300 IMPLANT $24,519 39 payments
  4. CORE $1,273 12 payments
  5. Cochlear Implantable hearing solution $185 3 payments
  6. Cochlear Implantable hearing solution $185 3 payments
  7. VIVAER STYLUS $183 1 payment
  8. RHINAER STYLUS $183 1 payment
  9. SCOPIS ENT $135 1 payment
  10. LATERA $135 1 payment
  11. Other $922 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

380

Median for Otolaryngology: 297

Drug cost

$8,980

Median for Otolaryngology: $6,314

Branded share of claims

19.5%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 40 $3,758
Ofloxacin Generic 124 $2,876
Fluocinolone Acetonide Oil Generic 27 $1,083
Mometasone Furoate Generic 20 $454
Ondansetron Hcl Generic 49 $240
Prednisone Generic 38 $227
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 34 $204
Cephalexin Generic 48 $138

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$203,417

Medicare's payments for the services billed

Medicare patients

352

Average age 75

Services billed

2,161

171 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 45%
Diabetes 26%
Ischemic heart disease 24%
Chronic kidney disease 22%
Atrial fibrillation 17%
Cancer 16%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otology & Neurotology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record